



BIOMÉRIEUX

VIDAS[®] CHIKUNGUNYA IgM, IgG

2 AUTOMATED TESTS FOR ACCURATE DIAGNOSIS




PIONEERING DIAGNOSTICS

Did you know?

Worldwide expansion over the last two decades^(1,2)

First identified in Tanzania in 1952, since 2004 CHIKV has spread rapidly to all continents, following the expansion of *Aedes albopictus* (tiger mosquito).



Chikungunya: a two-faced arboviral disease^(3,4)

The chikungunya virus (CHIKV) is transmitted to humans through the bites of infected *Aedes* mosquitoes.

ACUTE DISEASE

- CHIKV is usually responsible for a mild disease.
- At-risk patients can evolve to severe and sometimes (<1%) lethal complications.

CHRONIC DISEASE

- 40 to 60 % of patients evolve to a chronic phase.
- Inflammatory joint damages may persist for months or years and may lead to significant impairment of their quality of life.

What are the challenges of chikungunya diagnosis?^(3,4,5)

Chikungunya is a **widely underdiagnosed** disease with **non-specific symptoms**. Accurate differential diagnosis is essential to optimize patient management.

ACUTE DISEASE

The two main symptoms are fever and joint pain, sometimes associated with other non-specific symptoms (muscle pain, joint swelling, headache, nausea, fatigue, rash).

Depending on local epidemiology, differential diagnosis should consider several other infectious diseases, such as dengue, malaria...


CHRONIC DISEASE

The chronic phase should be distinguished from other inflammatory arthritis.

Etiological confirmation of chikungunya requires laboratory testing

- Viremia
- IgM
- IgG


Recommended diagnostic methods for chikungunya according to the time after the onset of symptoms. Adapted from Simon, Med Mal Infect, 2015⁽⁴⁾



VIDAS® CHIKUNGUNYA PANEL


EASY ACCESS TO AUTOMATION FOR CHIKUNGUNYA DIAGNOSIS

DETECTION FROM ACUTE TO CHRONIC DISEASE



CHKM IgM Antibody detection	CHKG IgG Antibody detection
<ul style="list-style-type: none"> • Early serological response • Immunocapture allows excellent performance⁽⁶⁾ 	<ul style="list-style-type: none"> • Detection of specific immunity • No cross reactivity⁽⁶⁾ with dengue, Zika, yellow fever and SARS-COV-2
High sensitivity on follow-up of CHIKV positive patients: 100% (11-21 days)⁽⁶⁾	

VIDAS® Anti-CHIKUNGUNYA IgM and IgG KINETICS



Developed with the contribution of the United States National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC)

RELIABLE & CLEAR-CUT RESULTS

- High-quality reagents based on bioMérieux's expertise in Infectious Diseases
- No equivocal zone
- Objective results
- Reliable performance thanks to automation
- Traceability

1 PLATFORM FOR OPTIMIZED DIAGNOSIS OF SEVERAL INFECTIOUS DISEASES



- Also available on your VIDAS® instrument:
- Dengue NS1, Anti-dengue IgM and Anti-dengue IgG
 - Comprehensive Infectious Diseases panel

Suspecting an arbovirus?

Think dengue AND chikungunya!

FLEXIBILITY

- 24/7 availability
- 2 independent assays
- Single test concept

EASE OF USE

- **Automated result interpretation**
- All reagents included in 1 kit
- Ready-to-use tests
- Just load & go

COST-EFFECTIVE SOLUTION

- **1 patient = 1 test**
- Calibration only once every 56 days
- Long shelf life
- Kit size adapted to the demand (30/60 tests)

ACCESSIBLE TO A WIDE RANGE OF LABORATORIES

AVAILABLE ON
INSTRUMENTS OF
THE VIDAS® FAMILY:
VIDAS®, MINI VIDAS®
AND VIDAS® 3



VIDAS® Anti-CHIKUNGUNYA IgM

VIDAS® Anti-CHIKUNGUNYA IgG

Reference	423229-30 / 423229	423230-30 / 423230
Tests / kit	30 / 60	30 / 60
Sample type	Serum	Serum
Calibration frequency	Only 56 days	Only 56 days
Shelf life	12 months	12 months

ECODESIGN - VIDAS® PACKAGING

- Water-based inks
- Varnish layer removal
- Pigments rationalization
- Weight reduction
- Flaps resizing



Save more than :



36 tons of paper per year



60 tons of CO₂ (-13%) emissions

VIDAS® ASSAY SOLUTIONS

PANEL INFECTIOUS DISEASES

	Ref	Kit size
COVID-19		
VIDAS SARS-COV-2 IgG II	424114	60 tests
VIDAS SARS-COV-2 IgG	423834	60 tests
VIDAS SARS-COV-2 IgM	423833	60 tests
TUBERCULOSIS		
VIDAS TB-IGRA*	423111	20 tests
VECTOR BORNE DISEASES		
VIDAS Anti-CHIKUNGUNYA IgM	423229-30	30 tests
VIDAS Anti-CHIKUNGUNYA IgG	423230-30	30 tests
VIDAS DENGUE NS1 Ag	423077	60 tests
VIDAS Anti-DENGUE IgM	423078	60 tests
VIDAS Anti-DENGUE IgG	423079	60 tests
VIDAS Lyme IgM	30319	60 tests
VIDAS Lyme IgG	30320	60 tests
HEPATITIS		
VIDAS HAV IgM	30307	30 tests
VIDAS Anti-HAV Total	30312	30 tests
VIDAS HBs Ag Ultra	30315	60 tests
VIDAS HBs Ag Ultra Confirmation	30317	30 tests
VIDAS Anti-HBs Total II	30318	60 tests
VIDAS Anti-HBc Total II	30314	60 tests
VIDAS HBc IgM II	30439	30 tests
VIDAS HBe/Anti-HBe	30305	30 tests
VIDAS Anti-HCV	30308	60 tests
VIDAS Anti-HEV IgM	418115	30 tests
VIDAS Anti-HEV IgG	418116	30 tests
HIV		
VIDAS HIV DUO Ultra	30443	60 tests
VIDAS HIV DUO Quick	30447	60 tests

	Ref	Kit size
VIDAS HIV P24 II	30117	30 tests
VIDAS HIV P24 II Confirmation	30444	60 tests
ToRC		
VIDAS TOXO IgM	30202	60 tests
VIDAS TOXO IgG II	30210	60 tests
VIDAS TOXO IgG Avidity	30222	30 tests
VIDAS TOXO Competition	30211	60 tests
VIDAS CMV IgM	30205	30 tests
VIDAS CMV IgG	30204	60 tests
VIDAS CMV IgG Avidity II	413557	30 tests
VIDAS RUB IgM	30214	30 tests
VIDAS RUB IgG II	30221	60 tests
ADDITIONAL SEROLOGIES		
VIDAS EBV VCA IgM	30237	30 tests
VIDAS EBV EBNA IgG	30235	30 tests
VIDAS EBV VCA/EA IgG	30236	30 tests
VIDAS Mumps IgG	30218	60 tests
VIDAS Measles IgG	30219	60 tests
VIDAS Varicella-Zoster IgG	30217	60 tests
VIDAS <i>H. pylori</i> IgG	30192	30 tests
ANTIGEN DETECTION		
VIDAS <i>C. difficile</i> Toxin A & B	30118	60 tests
VIDAS <i>C. difficile</i> GDH	30125	60 tests

EMERGENCY AND CRITICAL CARE

IMMUNOCHEMISTRY

PART OF THE VIDAS ASSAY RANGE FOR INFECTIOUS DISEASES



REFERENCES

- Weaver SC, Lecuit M: Chikungunya virus and the global spread of a mosquito-borne disease. *N Engl J Med* 2015, 372(13):1231-1239.
- WHO: Chikungunya Fact Sheet [https://www.who.int/news-room/fact-sheets/detail/chikungunya].
- CDC: Chikungunya. Information for healthcare providers. [https://www.cdc.gov/chikungunya/pdfs/CHIKV_Clinicians.pdf].
- Simon F, Javelle E, Cabie A, Bouquillard E, Troisgros O, Gentile G, Leparc-Goffart I, Hoen B, Gandjbakhch F, Rene-Corail P et al: French guidelines for the management of chikungunya (acute and persistent presentations). *November 2014. Med Mal Infect* 2015, 45(7):243-263.
- Natrajan MS, Rojas A, Waggoner JJ: Beyond Fever and Pain: Diagnostic Methods for Chikungunya Virus. *Journal of clinical microbiology* 2019, 57(6).
- VIDAS® Anti-CHIKUNGUNYA IgM and IgG package inserts.